Substantial humoral immune response observed in IBD patients after COVID-19 vaccine series
Click Here to Manage Email Alerts
LAS VEGAS – A humoral immune response after competition of COVID-19 vaccine series is detected in most patients with inflammatory bowel disease, including those on immunosuppressants, according to a presentation at the ACG Scientific Annual Meeting.
“The vast majority (95%) of IBD patients including those on immunosuppressive medications mounted an initial antibody response after completing the two-part mRNA SARS-CoV-2 vaccine series,” Kimberly N. Weaver, MD, assistant professor in the division of gastroenterology and hepatology at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, told Healio Gastroenterology. “This provides reassurance that most medications that we use to treat IBD do not substantially impact the response to the SARS-CoV-2 vaccine which is great news for our patients with Crohn’s disease and ulcerative colitis. Individuals with IBD treated with systemic corticosteroids and/or anti-TNF combination therapy may benefit the most from an additional dose of the SARS-CoV-2 vaccine, in accordance with CDC and FDA guidance.”
Weaver and colleagues enrolled 788 patients with IBD (mean age, 48 years; standard deviation, 16.1 years; 73% female) in the Partnership to Report Effectiveness of Vaccination in Populations Excluded from Initial Trials of COVID (PREVENT-COVID) prospective observational cohort study. These patients received any COVID-19 vaccine granted emergency use authorization in the United States including Johnson & Johnson, Moderna and Pfizer.
Eight weeks following completion of the COVID-19 vaccine series, patients had the opportunity to provide serum samples to assess antibody development. Investigators conducted quantitative analysis of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2. In addition, Weaver and colleagues conducted qualitative assessment of nucleocapsid antibodies as an indicator of past infection. This assessment included patients who completed a vaccination series and laboratory testing before June 17.
Investigators noted 752 patients (95.4%; 95% CI, 93.7%-96.7%) had detectable anti-RBD antibodies. Antibody response was similar across group, vaccine type and IBD medication class, although patients who received corticosteroids had decreased antibody response (n = 35). Of these, 85.7% (95% CI, 70.6%-93.7%) of patients had detectable antibodies compared with 95.9% (95% CI, 94.2%-97.1%) of non-steroid users.
Collapse
Weaver KN, et al. Abstract: S691. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Read more about
Click Here to Manage Email Alerts